Alivus Life Sciences · NSE: ALIVUS · BSE: 543322
Q3 FY24 results · Oct–Dec 2023
Alivus Life Sciences reported revenue from operations of ₹572.80 crore (up 5.9% from Q3 FY23) and net profit of ₹118.77 crore (up 13.1% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a standalone basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 572.80 | 540.73 | +5.9% | 595.36 | −3.8% |
| Other income | 1.69 | 6.61 | −74.4% | 5.37 | −68.5% |
| Total income | 574.50 | 547.34 | +5.0% | 600.73 | −4.4% |
| Profit before tax | 160.68 | 141.14 | +13.8% | 158.93 | +1.1% |
| Net profit for the period | 118.77 | 104.99 | +13.1% | 118.74 | +0.0% |
| EPS, basic (₹) | 9.69 | 8.57 | +13.1% | 9.69 | +0.0% |
| Net margin (%) | 20.7 | 19.4 | 19.9 |
Standalone
- Filed with BSE
- 24 Jan 2024, 08:22 IST
- Board meeting
- 23 Jan 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE